A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy

You may not be if

• Patients with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated.
• Signed informed consent
• The patients must have completed the FE 200486 CS21 Study.